Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).

Jennifer J. Knox,Mairéad G McNamara,Lipika Goyal,David O. Cosgrove,Christoph Springfeld,Katrin Marie Sjoquist,Joon Oh Park,Helena Verdaguer,Chiara Braconi,Paul Ross,Aimery de Gramont,Rachna T. Shroff,John Zalcberg,Daniel H. Palmer,Juan W. Valle

Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).

2021

Jennifer J. Knox
Mairéad G McNamara
Lipika Goyal
David O. Cosgrove
Christoph Springfeld
Katrin Marie Sjoquist
Joon Oh Park
Helena Verdaguer
Chiara Braconi
Paul Ross
Aimery de Gramont
Rachna T. Shroff
John Zalcberg
Daniel H. Palmer
Juan W. Valle

TPS351Background: Biliary tract cancer (BTC) carries a poor prognosis and no first-line treatments are approved. The accepted global standard of care is gemcitabine + cisplatin (GemCis). NUC-1031 i...

Keywords:

standard of care
Internal medicine
Gemcitabine
Cisplatin
Oncology
poor prognosis
Gemcitabine/cisplatin
biliary tract cancer
first line treatment
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations